Immune Defense Protein Impact On Respiratory Immune Outcomes

Part of paid clinical trials in Los Angeles, California.

Sponsor
Quantec Ltd
Study ID
NCT07431840
Status
Recruiting

Conditions

  • Influenza
  • Upper Respiratory Disease
  • Viral Upper Respiratory Infection

Eligibility Criteria

Sex
ALL
Age
60 Years - N/A
Healthy Volunteers
Accepted

Interventions

  • Immune Defense Protein 50mg Dose — DIETARY_SUPPLEMENT
    IDP dose of 50mg
  • IDP 200mg Dose — DIETARY_SUPPLEMENT
    IDP dose of 200mg
  • Matching Placebo — DIETARY_SUPPLEMENT
    Matching Placebo

Study Details

The primary goal of this study is to observe the impact of the IDP® Supplement on the duration and severity of upper respiratory symptoms in older individuals during the cold and flu season. Secondary aims include observing the product's effect on rescue medication use, quality of life, and overall tolerability. This is conducted as a consumer-driven, decentralized observational clinical research study in adults aged 60 or older, using self-reported measures and questionnaires completed at home via the Chloe App.

Key Dates

Start date
Dec 5, 2025
Status verified
Feb 2026
Primary completion
May 19, 2026
Completion
Jul 31, 2026

Study Design

Enrollment
300 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE

Arms

  • Experimental: Group 1: Study Product 50mg Dose
    50mg of Study Product
  • Experimental: Group 2: Study Product 200mg Dose
    200mg of Study Product
  • Placebo Comparator: Group 3: Matching Placebo
    Participants will receive Matching Placebo

Primary Outcome Measure

Impact on Upper Respiratory Symptom Incidence, Duration and Severity [ Time Frame: 17 weeks ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
People Science, Inc.Los AngelesCalifornia90045
Noah Craft, M.D., Ph.D
213-328-0919

Find similar trials in Los Angeles, CA

Related Studies